# US 2014/0194357 A1 · Modified Relaxin Polypeptides and Their Uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194357 A1
- Document ID: US20140194357A1
- Status: Published application
- Kind: A1
- Application number: 14/152,302
- Filed: 2014-01-10
- Published: 2014-07-10
- Earliest claimed: 2010-08-17
- Assignees: Ambrx, Inc.
- Applicants: Ambrx, Inc.
- Inventors: VADIM KRAYNOV; NICK KNUDSEN; AHMA HEWET; KRISTINE DE DIOS; JASON PINKSTAFF; LORRAINE SULLIVAN
- Web page: https://patentgrep.com/patent/US20140194357A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 38/2221: {Relaxins}
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/12: for climacteric disorders
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/64: Relaxins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Modified relaxin polypeptides and their uses thereof are provided

## Claims

### Claim at position 1

1-99. (canceled)

### Claim 100

A modified relaxin polypeptide comprising at least one non-naturally encoded amino acid.

### Claim 101

A nucleic acid comprising at least one selector codon, wherein said nucleic acid encodes a modified relaxin polypeptide.

### Claim 102 (depends on 100)

A method of treating a patient having a disorder modulated by relaxin, the method comprising administering to the patient a therapeutically effective amount of a composition comprising the modified relaxin polypeptide of claim 100.

### Claim 103 (depends on 100)

The modified relaxin polypeptide of claim 100, wherein said at least one non-naturally encoded amino acid is at a position selected from residues 1, 2, 5, 13 and 18 of the A chain of SEQ ID NO:4 or the corresponding position of said modified relaxin polypeptide, or residues 5 or 7 of the B chain of SEQ ID NO:5 or SEQ ID NO:6 or the corresponding position of said modified relaxin polypeptide.

### Claim 104 (depends on 101)

The nucleic acid of claim 101, wherein said at least one selector codon encodes a non-naturally encoded amino acid at a position selected from residues 1, 2, 5, 13 and 18 of the A chain of SEQ ID NO:4 or the corresponding position of said modified relaxin polypeptide, or residues 5 or 7 of the B chain of SEQ ID NO:5 or SEQ ID NO:6 or the corresponding position of said modified relaxin polypeptide.

### Claim 105 (depends on 102)

The method of claim 102, wherein said at least one non-naturally encoded amino acid is at a position selected from residues 1, 2, 5, 13 and 18 of the A chain of SEQ ID NO:4 or the corresponding position of said modified relaxin polypeptide, or residues 5 or 7 of the B chain of SEQ ID NO:5 or SEQ ID NO:6 or the corresponding position of said modified relaxin polypeptide.

### Claim 106 (depends on 100)

The modified relaxin polypeptide of claim 100, wherein said non-naturally encoded amino acid is linked to a linker, polymer, or biologically active molecule.

### Claim 107 (depends on 102)

The method of claim 102, wherein said non-naturally encoded amino acid is linked to a linker, polymer, or biologically active molecule.

### Claim 108 (depends on 106)

The modified relaxin polypeptide of claim 106, wherein said non-naturally encoded amino acid comprises a first functional group and the linker, polymer, or biologically active molecule comprises a second functional group, wherein the first functional group and second functional group are not identical and each comprise a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group, and the resultant covalent linkage created by the reaction of the first and second functional groups comprises an oxime linkage or a triazole.

### Claim 109 (depends on 107)

The method of claim 107, wherein said non-naturally encoded amino acid comprises a first functional group and the linker, polymer, or biologically active molecule comprises a second functional group, wherein the first functional group and second functional group are not identical and each comprise a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group, and the resultant covalent linkage created by the reaction of the first and second functional groups comprises an oxime linkage or a triazole.

### Claim 110 (depends on 106)

The modified relaxin polypeptide of claim 106, wherein said linker, polymer, or biologically active molecule comprises poly(ethylene glycol).

### Claim 111 (depends on 107)

The method of claim 107, wherein said linker, polymer, or biologically active molecule comprises poly(ethylene glycol).

### Claim 112 (depends on 102)

The method of claim 102, wherein the non-naturally encoded amino acid is selected from a phenylalanine analog, a phenylalanine derivative, para-acetyl-L-phenylalanine, para-azido-L-phenylalanine, or a para-substituted, ortho-substituted, or meta-substituted phenylalanine comprising a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group.

### Claim 113 (depends on 100)

The modified relaxin polypeptide of claim 100, wherein the relaxin polypeptide comprises a relaxin A chain polypeptide and a relaxin B chain polypeptide, wherein said relaxin A chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 4 and said relaxin B chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 5 or SEQ ID NO: 6.

### Claim 114 (depends on 101)

The nucleic acid of claim 101, which encodes at least one of a relaxin A chain polypeptide and a relaxin B chain polypeptide, wherein said relaxin A chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 4 and said relaxin B chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 5 or SEQ ID NO: 6.

### Claim 115 (depends on 102)

The method of claim 102, wherein the relaxin polypeptide comprises a relaxin A chain polypeptide and a relaxin B chain polypeptide, wherein said relaxin A chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 4 and said relaxin B chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 5 or SEQ ID NO: 6.

### Claim 116 (depends on 111)

The method of claim 111, wherein said poly(ethylene glycol) has an average molecular weight between about 0.1 kDa and about 100 kDa, between about 1 kDa and about 40 kDa, between about 5 kDa and about 40 kDa, or of about 20 kDa.

### Claim 117 (depends on 102)

The method of claim 102, wherein the modified relaxin polypeptide is therapeutically effective to decrease vasoconstriction, increase nitric oxide (NO) production, decrease platelet aggregation, decrease hypertrophy, decrease CF-stimulated protein synthesis, treat angiotensin-II (AngII)-mediated vasoconstriction, treat endothelin-1 (ET-1)-mediated vasoconstriction, increase ANP expression, or treat heart failure.

### Claim 118 (depends on 102)

The method of claim 102, wherein the non-naturally encoded amino acid has the structure:
wherein the R group is any substituent other than the side chain found in alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine.

### Claim 119 (depends on 102)

The method of claim 102, wherein said modified relaxin polypeptide exhibits an increase in in vivo half-life relative to the wild-type human relaxin polypeptide comprising the A chain polypeptide of SEQ ID NO:4 and the B chain polypeptide of SEQ ID NO:5, wherein the half-life is increased by an amount selected from at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold or at least 10-fold.
